Slovenia -
slovensk -
JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)
sunitinib teva 25 mg trde kapsule
sunitinib - kapsula, trda - sunitinib 25 mg / 1 kapsula - sunitinib
Slovenia -
slovensk -
JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)
sunitinib teva 50 mg trde kapsule
sunitinib - kapsula, trda - sunitinib 50 mg / 1 kapsula - sunitinib
Den europeiske union -
slovensk -
EMA (European Medicines Agency)
sunitinib accord
accord healthcare s.l.u. - sunitinib - gastrointestinal stromal tumors; carcinoma, renal cell; neuroendocrine tumors - antineoplastična sredstva - gastrointestinal stromal tumour (gist)sunitinib accord is indicated for the treatment of unresectable and/or metastatic malignant gastrointestinal stromal tumour (gist) in adults after failure of imatinib treatment due to resistance or intolerance. metastatic renal cell carcinoma (mrcc)sunitinib accord is indicated for the treatment of advanced/metastatic renal cell carcinoma (mrcc) in adults. pancreatic neuroendocrine tumours (pnet)sunitinib accord is indicated for the treatment of unresectable or metastatic, well-differentiated pancreatic neuroendocrine tumours (pnet) with disease progression in adults.
Slovenia -
slovensk -
JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)
sunitinib pharmascience 12,5 mg trde kapsule
sunitinib - kapsula, trda - sunitinib 12,5 mg / 1 kapsula
Slovenia -
slovensk -
JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)
sunitinib pharmascience 25 mg trde kapsule
sunitinib - kapsula, trda - sunitinib 25 mg / 1 kapsula
Slovenia -
slovensk -
JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)
sunitinib pharmascience 50 mg trde kapsule
sunitinib - kapsula, trda - sunitinib 50 mg / 1 kapsula
Slovenia -
slovensk -
JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)
lusmose 50 mg trde kapsule
sunitinib - kapsula, trda - sunitinib 50 mg / 1 kapsula - sunitinib
Den europeiske union -
slovensk -
EMA (European Medicines Agency)
sutent
pfizer limited - sunitinib - gastrointestinal stromal tumors; carcinoma, renal cell; neuroendocrine tumors - antineoplastična sredstva - gastrointestinal stromal tumour (gist)sutent is indicated for the treatment of unresectable and/or metastatic malignant gastrointestinal stromal tumour (gist) in adults after failure of imatinib mesilate treatment due to resistance or intolerance. metastatic renal cell carcinoma (mrcc)sutent is indicated for the treatment of advanced/metastatic renal cell carcinoma (mrcc) in adults. pancreatic neuroendocrine tumours (pnet)sutent is indicated for the treatment of unresectable or metastatic, well-differentiated pancreatic neuroendocrine tumours with disease progression in adults. experience with sutent as first-line treatment is limited (see section 5.
Slovenia -
slovensk -
JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)
natrijev levotiroksinat norpharm regulatory services 100 mikrogramov/ 5 ml
norpharm regulatory services ltd - natrijev levotiroksinat - peroralna raztopina - natrijev levotiroksinat 100 µg / 100 ml - natrijev levotiroksinat
Slovenia -
slovensk -
JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)
natrijev levotiroksinat norpharm regulatory services 50 mikrogramov/ 5 ml
norpharm regulatory services ltd - natrijev levotiroksinat - peroralna raztopina - natrijev levotiroksinat 50 µg / 100 ml - natrijev levotiroksinat